Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Dalotuzumab

😃Good
Catalog No. T76800Cas No. 1005389-60-5
Alias MK-0646, h7C10

Dalotuzumab (MK-0646) is a recombinant humanized IgG1 monoclonal antibody that specifically targets the insulin-like growth factor 1 receptor (IGF-1R). its mechanism of action involves the inhibition of IGF-mediated oncogenic signaling, which subsequently induces apoptosis and cell cycle arrest in tumor cells, and it has demonstrated enhanced antitumor efficacy when used in combination with other chemotherapeutic agents.

Dalotuzumab

Dalotuzumab

😃Good
Catalog No. T76800Alias MK-0646, h7C10Cas No. 1005389-60-5
Dalotuzumab (MK-0646) is a recombinant humanized IgG1 monoclonal antibody that specifically targets the insulin-like growth factor 1 receptor (IGF-1R). its mechanism of action involves the inhibition of IGF-mediated oncogenic signaling, which subsequently induces apoptosis and cell cycle arrest in tumor cells, and it has demonstrated enhanced antitumor efficacy when used in combination with other chemotherapeutic agents.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$247-In Stock
5 mg$645-In Stock
10 mg$987-In Stock
25 mg$1,460-In Stock
50 mg$1,970-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:97.6% (SDS-PAGE); 99.3% (SEC-HPLC)
Contact us for more batch information

Product Introduction

Bioactivity
Description
Dalotuzumab (MK-0646) is a recombinant humanized IgG1 monoclonal antibody that specifically targets the insulin-like growth factor 1 receptor (IGF-1R). its mechanism of action involves the inhibition of IGF-mediated oncogenic signaling, which subsequently induces apoptosis and cell cycle arrest in tumor cells, and it has demonstrated enhanced antitumor efficacy when used in combination with other chemotherapeutic agents.
In vitro
Dalotuzumab (33 nM, 24 h) was used to treat IGF-1-induced MCF7 cells, and the changes in cell cycle and the expression of IGF-IR and IRS-1 proteins were detected. Results: Dalotuzumab was able to induce cell cycle arrest in IGF-1-induced MCF7 cells and also inhibited the autophosphorylation of IGF-IR and IRS-1. [1]
In vivo
Methods: Dalotuzumab (MK-0646) (250 µg/mouse initially, then 125 µg/mouse, intraperitoneally twice a week for 40 days) was used to treat Swiss nude mice bearing MCF-7 and A549 xenograft tumors, and its tumor inhibition was observed. Results: Dalotuzumab reduced the average tumor volume of nude mice in the MCF-7 and A549 models by 70% and 72%, respectively. [1]
SynonymsMK-0646, h7C10
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetIGF1-R/IGFR1/CD221
Chemical Properties
Molecular Weight146.36 kDa
Cas No.1005389-60-5
ColorTransparent
AppearanceLiquid
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Dalotuzumab | purchase Dalotuzumab | Dalotuzumab cost | order Dalotuzumab | Dalotuzumab in vivo | Dalotuzumab in vitro | Dalotuzumab molecular weight